Sphingosine 1-phosphate pathway therapeutics: A lipid ligand-receptor paradigm

Current Opinion in Chemical Biology

Volumn 7, Issue 4, 2003, Pages 461-468

  Rosen, Hugh ^a   Liao, Jiayu ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; DRUG ANALOG; FINGOLIMOD; G PROTEIN COUPLED RECEPTOR; LIGAND; LIPID; RECEPTOR; RECEPTOR SUBTYPE; SPHINGOMYELIN PHOSPHODIESTERASE INHIBITOR; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; BIOSYNTHESIS; CANCER GROWTH; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HYDROPHOBICITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LIGAND BINDING; LIPID ANALYSIS; LIPOGENESIS; LYMPHOCYTE; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE;

EID: 0043073128     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(03)00085-1     Document Type: Review

References (63)

1. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., Thornton R., Shei G.J., Card D., Keohane C.et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 296:2002;346-349 The first determination of the receptor mechanism of action of FTY720-P and formal evidence for inhibition of lymphocyte egress from lymph node into lymph by the non-hydrolyzable FTY-phosphonate.
2. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., Bruns C., Prieschl E., Baumruker T., Hiestand P.et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 277:2002;21453-21457 Confirmation of the S1P receptor basis of FTY720 action.
3. Brinkmann V., Lynch K. FTY720: targeting G-protein-coupled receptors for S1P in transplantation and autoimmunity. Curr Opin Immunol. 14:2002;569-575.
4. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest. 110:2002;3-8.
5. Spiegel S., Kolesnick R. Sphingosine 1-phosphate as a therapeutic agent. Leukemia. 16:2002;1596-1602.
6. Spiegel S., Milstien M. Sphingosine 1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 4:2003;397-407.
7. Igarashi J., Michel T. Agonist-modulated targeting of the EDG-1 receptor to plasmalemmal caveolae. eNOS activation by sphingosine 1-phosphate and the role of caveolin-1 in sphingolipid signal transduction. J Biol Chem. 275:2000;32363-32370.
8. Xia P., Wang L., Gamble J.R., Vadas M.A. Activation of sphingosine kinase by TNF-alpha inhibits apoptosis in human endothelial cells. J Biol Chem. 274:1999;34499-34505.
9. Melendez A., Floto R.A., Gillooly D.J., Harnett M.M., Allen J.M. FcgR1 coupling to phospholipase D initiates sphingosine kinase mediated calcium mobilization and vesicular trafficking. J Biol Chem. 273:1998;9393-9402.
10. Olivera A., Spiegel S. S1P as a second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature. 365:1993;557-560.
11. Yatomi Y., Ohmori T., Rile G., Kazama F., Okamoto H., Sano T., Satoh K., Kume S., Tigyi G., Igarashi Y., Ozaki Y. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood. 96:2000;3431-3438 Demonstration of the importance of preformed stores of S1P in platelets.
12. Chun J., Goetzl E.J., Hla T., Igarashi Y., Lynch K.R., Moolenaar W., Pyne S., Tigyi G. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev. 54:2002;265-269.
13. Takuwa Y. Subtype-specific differential regulation of Rho family G proteins and cell migration by the Edg family sphingosine-1-phosphate receptors. Biochimica Biophysica Acta. 1582:2002;112-120.
14. English D., Brindley D.N., Spiegel S., Garcia J.G. Lipid mediators of angiogenesis and the signalling pathways they initiate. Biochimica Biophysica Acta. 1582:2002;228-239.
15. Garcia J.G.N., Liu F., Verin A.D., Birukova A., Dechert M.A., Gerthoffer W.T., Bamberg J.R., English D. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest. 108:2001;689-701 A role for S1P receptors in the maintenance of endothelial barriers that might be of therapeutic import.
16. Sugimoto N., Takuwa N., Okamoto H., Sakurada S., Takuwa Y. Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol Cell Biol. 23:2003;1534-1545 The importance of multiple coupling pathways for transduction by the S1P system.
17. Hobson J.P., Rosenfeldt H.M., Barak L.S., Olivera A., Poulton S., Caron M.G., Milstien S., Spiegel S. Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science. 291:2001;1800-1803.
18. Murata N., Sato K., Kon J., Tomura H., Yanagita M., Kuwabara A., Ui M., Okajima F. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J. 352:2000;809-815 Bound versus free ligand is a truism that is sometimes neglected.
19. Mandala S.M., Thornton R., Galve-Roperh I., Poulton S., Peterson C., Olivera A., Bergstrom J., Kurtz M.B., Spiegel S. Molecular cloning and characterization of a lipid phosphohydrolase that degrades sphingosine-1- phosphate and induces cell death. Proc Natl Acad Sci USA. 97:2000;7859-7864.
20. Liliom K., Sun G., Bunemann M., Virag T., Nusser N., Baker D.L., Wang D.A., Fabian M.J., Brandts B., Bender K.et al. Sphingosylyphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. Biochem J. 355:2001;189-197 Effects on cardiac function always matter.
21. Mazurais D., Robert P., Gout B., Berrebi-Bertrand I., Laville M.P., Calmels T. Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem. 50:2002;661-669 Effects on cardiac function always matter.
22. Mayer zu Heringdorf D., Lass H., Kuchar I., Lipinski M., Alemany R., Rumenapp U., Jakobs K.H. Stimulation of intracellular sphingosine-1-phosphate production by G-protein-coupled sphingosine-1-phosphate receptors. Eur J Pharmacol. 414:2001;145-154.
23. Dantas A.P.V., Igarashi J., Michel T. Sphingosine 1-phosphate and control of vascular tone. Am J Physiol Heart Circ Physiol. 284:2003;H2045-H2052 This paper defines the role of S1P in regulation of vascular tone.
24. Rosen H, Sanna M, Alfonso C: Egress: a receptor-regulated step in lymphocyte trafficking. Immunol Rev 2003, in press.
25. Brinkmann V., Lynch K. FTY720: targetting G-protein coupled receptors for spingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol. 14:2002;569-575.
26. Brinkmann V., Pinschewer D., Chiba K., Feng L. FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci. 21:2000;49-52.
27. Parrill A.L., Wang D., Bautista D.L., Van Brocklyn J.R., Lorincz Z., Fischer D.J., Baker D.L., Liliom K., Spiegel S., Tigyi G. Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate. J Biol Chem. 275:2000;39379-39384 A useful binding model for S1P.
28. Sardar V.M., Bautista D.L., Fischer D.J., Yokoyama K., Nusser N., Virag T., Wang D.A., Baker D.L., Tigyi G., Parrill A.L. Molecular basis for the lysophosphatidic acid receptor agonist selectivity. Biochim Biophys Acta. 1582:2002;309-317 A useful binding model for lysophosphatidic acid.
29. Seko T, Terakado M, Kohno H, Takahashi S: Carboxylic Acid Derivatives and Drugs Containing the same as Active Ingredient. 2002, PCT WO 02/092068, Ono Pharmaceutical Co., Ltd: Japan:79.
30. Brunkhorst R., Neumayer H.H., Hiss M., Budde K., Lucker P., Mayer T., Brookman L., Schmouder R. Human safety and pharmacology of FTY 720. Transplantation. 67:1999;S153.
31. Neumayer H.H., Brunkhorst R., Budde K., Hiss M., Lucker P., Mayer T., Choudhury S., Kraus G., Schmouder R. Human pharmacokinetics of FTY 720. Transplantation. 67:1999;S204.
32. Uhlenbrock K., Gassenhuber H., Kostenis E.U. Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors. Cell Signal. 14:2002;941-953.
33. Kabarowski J.H., Zhu K., Le L.Q., Witte O.N., Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science. 293:2001;702-705 The lysophosphatidylcholine receptor G2A plays a role in the long term suppression of autoimmunity, and presumably the maintenance of tolerance.
34. Le L.Q., Kabarowski J.H., Weng Z., Satterthwaite A.B., Harvill E.T., Jensen E.R., Miller J.F., Witte O.N. Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity. 14: 2001;561-571 The lysophosphatidylcholine receptor G2A plays a role in the long term suppression of autoimmunity, and presumably the maintenance of tolerance.
35. Sugiyama A., Yatomi Y., Ozaki Y., Hashimoto K. Sphingosine 1-phosphate induces sinus tachycardia and coronary vasoconstriction in the canine heart. Cardiovasc Res. 46:2000;119-125 Coronary artery vasospasm can be mediated by S1P - a potential adverse effect or therapeutic opportunity for antagonists?
36. 2/edg5 may be the culprit in coronary artery vasospasm?
37. B3/EDG-3. J Biol Chem. 276:2001;33697-33704.
38. 3/Edg-3. J Biol Chem. 277:2002;25152-25159.
39. Allende M.L., Proia R.L. Sphingosine-1-phosphate receptors and the development of the vascular system. Biochimica Biophysica Acta. 1582:2002;222-227.
40. Liu Y., Wada R., Yamashita T., Mi Y., Deng C.X., Hobson J.P., Rosenfeldt H.M., Nava V.E., Chae S.S., Lee M.J.et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest. 106:2000;951-961 A classic paper elucidating the role of Edg-1 in vascular maturation.
41. Yagi H., Kamba R., Chiba K., Soga H., Yaguchi K., Nakamura M., Itoh T. Immunosuppressant FTY720 inhibits thymocyte emigration. Eur J Immunol. 30:2000;1435-1444.
42. Chiba K., Hoshino Y., Suzuki C., Masubuchi Y., Yanagawa Y., Ohtsuki M., Sasaki S., Fujita T. FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant Proc. 28:1996;1056-1059.
43. Chiba K., Yanagawa Y., Masubuchi Y., Kataoka H., Kawaguchi T., Ohtsuki M., Hoshino Y. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol. 160:1998;5037-5044.
44. Chiba K., Yanagawa Y., Kataoka H., Kawaguchi T., Ohtsuki M., Hoshino Y. FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing. Transplant Proc. 31:1999;1230-1233.
45. Xie J., Nomura N., Koprak S.L., Quackenbush E.J., Forrest M.J., Rosen H. Sphingosine-1-phosphate receptor agonists impair the efficiency of the local immune response by altering trafficking of naïve and antigen-activated CD4+ T cells. J Immunol. 170:2003;3662-3670 S1P receptor agonists alter efficiency of local immune responses by misdirecting CD4+ T cells.
46. Pinschewer D.D., Ochsenbein A.F., Odermatt B., Brinkmann V., Hengartner H., Zinkernagel R.M. FTY720 immunosuppression impairs effector T-cell peripheral homing without affecting induction, expansion, and memory. J Immunol. 164:2000;5761-5770 Misdirection of lymphocytes from spleen to lymph nodes does not impair CD8 effector responses, nor the acquisition of B cell memory to systemic antigens.
47. Matsuura M., Imayoshi T., Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats. Int J Immunol. 22:2000;323-331.
48. Budde K., Schmouder R.L., Brunkhorst R., Nashan B., Lucker P.W., Mayer T., Choudhury S., Skerjanec A., Kraus G., Neumayer H.H. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol. 13:2002;1073-1083 FTY720 works at picomolar blood concentrations.
49. Bohler T, Waiser J, Schutz M, Friedrich M, Schotschel R, Reinhold S, Schmouder R, Budde K, Neumayer HH: FTY720 mediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis-independent mechanism. Transpl Int 2000, 13(Suppl 1):S311-313.
50. Honig S.M., Fu S., Mao X., Yopp A., Gunn M.D., Randolph G.J., Bromberg J.S. FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. J Clin Invest. 111:2003;627-637.
51. Cuvillier O., Levade T. Enzymes of sphingosine metabolism as potential pharmacological targets for therapeutic intervention in cancer. Pharmacol Res. 47:2003;439-445 Review of the enzymology as currently understood.
52. Cremesti A., Paris F., Grassme H., Holler N., Tschopp J., Fuks Z., Gulbins E., Kolesnick R. Ceramide enables Fas to cap and kill. J Biol Chem. 276:2001;23954-23961 How ceramide may work!
53. Charles R., Sandirasegarane L., Yun J., Bourbon N., Wilson R., Rothstein R.P., Levison S.W., Kester M. Ceramide-coated balloon catheters limit neointimal hyperplasia after stretch injury in carotid arteries. Circ Res. 87:2000;282-288 Therapeutic exploitation of ceramide itself.
54. Tilly J., Kolesnick R. Sphingolipids, apoptosis, cancer treatments and the ovary: investigating a crime against female fertility. Biochim Biophys Acta. 1585:2002;135-138.
55. Paris F., Perez G.I., Fuks Z., Haimovitz-Friedman A., Nguyen H., Bose M., Ilagan A., Hunt P.A., Morgan W.F., Tilly J.L., Kolesnick R. Sphingosine 1-phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring. Nat Med. 8:2002;901-902 Novel mechanisms by which S1P may have therapeutic benefits.
56. Permpongkosol S., Wang J.D., Takahara S., Matsumiya K., Nonomura N., Nishimura K., Tsujimura A., Kongkanand A., Okuyama A. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int J Cancer. 98:2002;167-172.
57. Suzuki S., Li X.K., Shinomiya T., Enosawa S., Amemiya H., Amari M., Naoe S. The in vivo induction of lymphocyte apoptosis in MRL-1pr/1pr mice treated with FTY720. Clin Exp Immunol. 107:1997;103-111.
58. Fujino M., Li X.K., Guo L., Kitazawa Y., Funeshima N., Fukuda S., Kimura H., Miyashita T., Okuyama T., Amano T., Suzuki S. T cell apoptosis triggered by FTY720 via mitochondrial pathway. Transplant Proc. 33:2001;3084-3085.
59. Fujino M., Li X.K., Guo L., Amano T., Suzuki S. Activation of caspases and mitochondria in FTY720-mediated apoptosis in human T cell line Jurkat. Int Immunopharmacol. 1:2001;2011-2021.
60. Fujino M., Li X.K., Kitazawa Y., Guo L., Kawasaki M., Funeshima N., Amano T., Suzuki S. Distinct pathways of apoptosis triggered by FTY720, etoposide, and anti-Fas antibody in human T-lymphoma cell line (Jurkat cells). J Pharmacol Exp Ther. 300:2002;939-945.
61. Nagahara Y., Ikekita M., Shinomiya T. Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria. J Immunol. 165:2000;3250-3259.
62. Nagahara Y., Enosawa S., Ikekita M., Suzuki S., Shinomiya T. Evidence that FTY720 induces T cell apoptosis in vivo. Immunopharmacology. 48:2000;75-85.
63. Nagahara Y., Ikekita M., Shinomiya T. FTY729 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria. J Immunol. 165:2000;3250-3259.